Literature DB >> 28643276

A Rapid Two-Step Iduronate-2-Sulfatatse Enzymatic Activity Assay for MPSII Pharmacokinetic Assessment.

Mitra Azadeh1, Luying Pan2, Yongchang Qiu2, Ruben Boado3.   

Abstract

Clinical studies involving enzyme replacement therapies (ERTs) have increasingly utilized enzymatic activity assays to monitor efficacy and biofunction of the drug; as a result, these assays have become an important part of pharmacokinetic (PK) and pharmacodynamic assessments in ERT trials. This paper presents a two-step enzymatic activity assay for iduronate-2-sulfatase (I2S) (EC 3.1.6.13) which we have optimized to fit in 1 day and to complete in less than 6 h. The rapid assay presented here is a significant improvement over the original two-step method with run time of 24 h which spanned 2 days. The resulting 1 day assay is efficient, robust, reproducible, and better suited for use in pharmacokinetic studies. The method was fully validated in accordance with regulatory agency guidelines so that it could be implemented in PK studies. Validation of the method required additional modifications to circumvent limitations surrounding the calculation of accuracy. This challenge was overcome by developing strategies to determine both the expected and the measured values of validation samples in activity units. Subsequently, the method was validated in accordance with the FDA guidance for the validation of quantitative ligand binding assays (LBAs). Results of method development and optimization with focus on evaluations aimed at reducing the total assay run time as well as a summary of method validation performance are presented in this publication.

Entities:  

Keywords:  ERT; Enzymatic activity assay; Hunter Syndrome; I2S; MPSII; α-L-iduronidase

Year:  2017        PMID: 28643276      PMCID: PMC5874215          DOI: 10.1007/8904_2017_34

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  10 in total

1.  Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules.

Authors:  Binodh DeSilva; Wendell Smith; Russell Weiner; Marian Kelley; JoMarie Smolec; Ben Lee; Masood Khan; Richard Tacey; Howard Hill; Abbie Celniker
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

2.  Fluorometric determination of arylsulfatase A and B activities.

Authors:  H Inoue; E Usami; Y Seyama; S Yamashita
Journal:  Chem Pharm Bull (Tokyo)       Date:  1982-11       Impact factor: 1.645

3.  A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).

Authors:  Joseph Muenzer; Muge Gucsavas-Calikoglu; Shawn E McCandless; Thomas J Schuetz; Alan Kimura
Journal:  Mol Genet Metab       Date:  2006-12-20       Impact factor: 4.797

4.  alpha-L-iduronidase, beta-D-glucuronidase, and 2-sulfo-L-iduronate 2-sulfatase: preparation and characterization of radioactive substrates from heparin.

Authors:  J J Hopwood
Journal:  Carbohydr Res       Date:  1979-03       Impact factor: 2.104

5.  A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spots.

Authors:  Adviye A Tolun; Carrie Graham; Qun Shi; Ramakrishna S Sista; Tong Wang; Allen E Eckhardt; Vamsee K Pamula; David S Millington; Deeksha S Bali
Journal:  Mol Genet Metab       Date:  2011-12-21       Impact factor: 4.797

6.  A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease).

Authors:  Y V Voznyi; J L Keulemans; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  2001-11       Impact factor: 4.982

7.  Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.

Authors:  Jeff Zhiqiang Lu; Eric Ka-Wai Hui; Ruben J Boado; William M Pardridge
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

8.  Diagnosing lysosomal storage disorders: mucopolysaccharidosis type II.

Authors:  Britt A Johnson; Otto P van Diggelen; Angela Dajnoki; Olaf A Bodamer
Journal:  Curr Protoc Hum Genet       Date:  2013-10-18

9.  Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.

Authors:  Ruben J Boado; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; William M Pardridge
Journal:  Biotechnol Bioeng       Date:  2014-08-05       Impact factor: 4.530

10.  A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).

Authors:  Joseph Muenzer; James E Wraith; Michael Beck; Roberto Giugliani; Paul Harmatz; Christine M Eng; Ashok Vellodi; Rick Martin; Uma Ramaswami; Muge Gucsavas-Calikoglu; Suresh Vijayaraghavan; Susanne Wendt; Suzanne Wendt; Ana Cristina Puga; Antonio Puga; Brian Ulbrich; Marwan Shinawi; Maureen Cleary; Diane Piper; Anne Marie Conway; Ann Marie Conway; Alan Kimura
Journal:  Genet Med       Date:  2006-08       Impact factor: 8.822

  10 in total
  1 in total

1.  Quality Controls in Ligand Binding Assays: Recommendations and Best Practices for Preparation, Qualification, Maintenance of Lot to Lot Consistency, and Prevention of Assay Drift.

Authors:  Mitra Azadeh; Perceval Sondag; Ying Wang; Maribeth Raines; Jeffrey Sailstad
Journal:  AAPS J       Date:  2019-07-11       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.